Other genes showed relatively lower alteration frequencies in CMTs than in human breast cancers, including TP53 (inactivated in 0%, 15%, and 48% of benign CMTs, malignant CMTs, and human breast cancers, respectively), as well as EGFR, ERBB2, ATM, and CHEK2. In addition, AKT3, MDM2, and MDM4 were rarely altered in CMTs. This evidence concerns the gene ERBB2 and breast carcinoma.